Smart strategies to early drug development

Drug Development Smart Strategies:

 1. Partnerability:

Partnering
is a core element for most Biotech business models. Partnering at the optimal
point of their asset. Optimal Point is defined by proactively updating when new
information arrives:

• Scientific
  read-out
• Competitive
  Landscape
• Recent
  deals
• Regulatory
  decisions
• etc…

2. Maximising return of investment:

Generation
of cost-effective data will influence drug projects at Biotech

1. Maximum
   exploitation of projects supported by science to find commercial paths
2. Investor’s
   appetite increase, planning of fund raising campaigns
3. Prospective
   Partnering discussions: collection of ‘hints’
4. Conscious
   choice making (e.g. delaying CMC upscaling work, etc …)

3. Lean and flexible Project Management: 

1. Dealing
   with resource constraints versus generation of several viable indications
   1. Therapeutic
      areas/Sub-Indications
   2. Different
      routes of administration
   3. Place
      in therapy (mono versus combination, first line therapy versus
      refractory)
2. Value
   the service provider
   1. Innovative
      compounds
   2. Open
      communication
   3. Tap
      into experience

Learn more about this topic with our course on:

Bridging Preclinical and Clinical Development 

Written by Kristof Vercruysse – 9 Jan. 2019